Amicus Therapeutics, Inc.  

(Public, NASDAQ:FOLD)   Watch this stock  
Find more results for FOLD
14.61
-1.17 (-7.41%)
After Hours: 14.87 +0.26 (1.78%)
Sep 22, 6:58PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.59 - 15.70
52 week 4.41 - 16.06
Open 15.63
Vol / Avg. 4.27M/3.60M
Mkt cap 2.40B
P/E     -
Div/yield     -
EPS -1.46
Shares 164.57M
Beta 1.82
Inst. own 108%
Nov 6, 2017
Q3 2017 Amicus Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 27, 2017
Amicus Therapeutics Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology - 1:00PM EDT - Add to calendar
Sep 13, 2017
Amicus Therapeutics Inc to Discuss Top-Line Phase 3 Essence Study Results - Webcast
Aug 7, 2017
Q2 2017 Amicus Therapeutics Inc Earnings Release
Aug 7, 2017
Q2 2017 Amicus Therapeutics Inc Earnings Call - Webcast
Jul 11, 2017
Amicus Therapeutics Inc Conference Call to Discuss its Amicus Therapeutics U.S. Pathway and Upcoming NDA Submission for Migalastat - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -672.48% -4034.73%
Operating margin -657.46% -3936.91%
EBITD margin - -3601.84%
Return on average assets -19.98% -20.57%
Return on average equity -66.85% -56.51%
Employees 263 -
CDP Score - -

Address

1 Cedarbrook Dr
CRANBURY, NJ 08512-3618
United States - Map
+1-609-6622000 (Phone)
+1-609-6622001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Officers and directors

John F. Crowley J.D. Chairman of the Board, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Bradley L. Campbell President, Chief Operating Officer
Age: 41
Bio & Compensation  - Reuters
William D. Baird III Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Daphne E. Quimi Senior Vice President - Finance and Administration, Corporate Controller
Age: 51
Bio & Compensation  - Reuters
Kurt J. W. Andrews Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
Hung Viet Do Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Ellen S. Rosenberg General Counsel and Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Jay A. Barth M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Donald J. Hayden Jr. Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Robert A. Essner Independent Director
Age: 70
Bio & Compensation  - Reuters